Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
PKC beta protein kinase inhibitor LY 333531 mesylate, 1 mg  

PKC beta protein kinase inhibitor LY 333531 mesylate, 1 mg

13-((Dimethylamino)methyl)-10,11,14,15-tetrahydro-4,9:16,21 -dimetheno-1H,13H-dibenzo(e,k)pyrrolo(3,4-h)(1,4,13) oxadiazacyclohexadecene-1,3(2H)-dione methanesulfonate

Synonyms: Ruboxistaurin
LY 333531 mesylate is an orally active protein kinase C β (PKC-β) specific inhibitor.

More details

PKI-LY333-001

Availability: within 3 days

117,00 €

Background: LY 333531 mesylate / Ruboxistaurin is an orally active protein kinase C β (PKC-β) specific inhibitor; a salt form that is five times more water-soluble than its hydrochloride salt.
The hydrochloride salt of LY 333531 is available as well.

Chemical formula: C28H28N4O3.CH4O3S
Molecular weight: 564.65 g/mol
Purity: 99 %
Appearance: Dark Red Solid
Solubility: Soluble in DMSO
CAS Number: 192050-59-2

Manufacturer:  Axon Medchem BV

PLEASE NOTE: This product is designed for research purposes and can only be delivered to academic and business customers.  

References

GL Engel et al. Salt form selection and characterization of LY333531 mesylate monohydrate. Int. J. Pharmaceutics 2000, 198(2), 239-247.
 
MR Jirousek et al. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacy clohexadecene-1,3(2H)-dione (LY333531) and related analogues: (...). J. Med. Chem. 1996, 39, 2664.
 
Y Wu et al. Protein kinase C beta inhibitor LY333531 attenuates intercellular adhesion molecule-1 and monocyte chemotactic protein-1 expression in the kidney in diabetic rats. J. Pharmacol. Sci. 2006, 101(4), 335-343.